NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

NRx Pharmaceuticals, Inc.

A pharmaceutical company focused on developing innovative therapies for the treatment of central nervous system disorders and life-threatening pulmonary conditions.

NRx Pharmaceuticals

Understanding the role of Vasoactive Intestinal Peptide (VIP) in treating COVID-19

NeuroRx: Understanding our science

NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience to address very high unmet needs of patients and bring improved health to patients. The U.S. Food and Drug Administration (“FDA”) has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue		1.01M -		907.41K -			5K -
gross profit		-1.01M -		-907.41K -			-5K -
selling and marketing expenses							-5K -
general and administrative expenses				11.44M -	74.94M 555.33%	27.37M 63.48%	14.22M 48.06%
selling general and administrative expenses				11.44M -	74.94M 555.33%	27.37M 63.48%	14.21M 48.08%
research and development expenses				10.63M -	20.26M 90.65%	17.03M 15.95%	13.37M 21.47%
other expenses		1.01M -	713.19K 29.14%	-10.16M 1,524.59%	-771K 92.41%	-505K 34.50%	250K 149.50%
cost and expenses		1.01M -	713.19K 29.14%	11.90M 1,568.71%	94.43M 693.46%	44.40M 52.98%	27.59M 37.86%
operating expenses		1.01M -	713.19K 29.14%	11.90M 1,568.71%	94.43M 693.46%	44.40M 52.98%	27.58M 37.87%
interest expense				56K -	18K 67.86%	-4.58M 25,550%	120K 102.62%
ebitda		82.41K -	492.63K 497.77%	-51.38M 10,530.69%	-115.79M 125.35%	-44.65M 61.44%	-27.58M 38.23%
operating income		-1.01M -	-713.19K 29.14%	-51.39M 7,105.26%	-115.80M 125.34%	-44.40M 61.66%	-27.59M 37.86%
depreciation and amortization		1.09M -	1.21M 10.74%	2K 99.83%	2K 0%	-256K 12,900%	5K 101.95%
total other income expenses net		1.09M -	1.21M 10.74%	-390K 132.34%	22.73M 5,928.97%	4.58M 79.85%	-2.56M 155.95%
income before tax		82.41K -	492.63K 497.77%	-51.78M 10,610.26%	-93.06M 79.74%	-39.82M 57.22%	-30.15M 24.28%
income tax expense		16.31K -	84.21K 416.25%	-39.43M 46,925.64%	-21.35M 45.86%	-4.58M 78.54%
net income		66.10K -	408.43K 517.88%	-12.35M 3,123.06%	-71.72M 480.83%	-35.23M 50.87%	-30.15M 14.43%
weighted average shs out	2.61M -	2.61M 0%	2.78M 6.45%	34.27M 1,131.43%	46.92M 36.90%	65.77M 40.17%	75.76M 15.20%
weighted average shs out dil	2.61M -	2.61M 0%	2.78M 6.45%	34.27M 1,131.43%	46.92M 36.90%	65.77M 40.17%	75.76M 15.20%
eps	0 -	0.03 Infinity%	0.15 492.89%	-0.36 340.00%	-1.53 325%	-0.54 64.71%	-0.40 25.93%
epsdiluted	0 -	0.03 Infinity%	0.15 492.89%	-0.36 340.00%	-1.53 325%	-0.54 64.71%	-0.40 25.93%

COM:NRXPHARMA

NRx Pharmaceuticals

Last Close

1.23

22/11 21:00

Market Cap

25.25M

Beta: -

Volume Today

79.66K

Avg: -

Preview